This Week in Pediatric Oncology

By Solving Kids' Cancer

Solving Kids' Cancer explores new advances in childhood cancer with host Dr. Timothy Cripe from Nationwide Children's Hospital... more

4.4

1818 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about This Week in Pediatric Oncology:

How many episodes does This Week in Pediatric Oncology have?

The podcast currently has 115 episodes available.

This Week in Pediatric Oncology episodes:

February 10, 2014 TWiPO #24 ~ Cord Blood Banking: Interview with Machi Scaradavou
March
06, 2012
Dr. Tim Cripe welcomes Dr. Andy Kolb from AI
DuPont in this episode of TWiPO, and special guest Dr. Andromachi Scaradavou,
the Medical Director of New York Blood Center's National Cord Blood Program.
NYBC is the world's oldest and largest public
cord blood bank, and collects, processes, tests and stores cord blood that
mothers donate shortly after birth. The cord blood is for children and adults
with no related donor available who need a hematopoietic stem cell transplant
for life-threatening illnesses. More than 60,000 units are stored at NYBC and
more than 4500 units have been provided for transplants worldwide. The variety
of ethic groups represented is much higher in cord blood banking than in bone
marrow donor programs. The percentage of use is climbing significantly for
pediatric transplants partly because of the small dose required.
Discussants cover many aspects of this
fascinating subject: background and uses of cord blood, logistics of
collecting, processing, storing, and selecting units for transplants, as well
as the advantages and challenges currently faced in this field. For more on
NYBC seehttp://www.nationalcordbloodprogram.org/
We welcome all questions or comments at
[email protected]
...more
32min
February 10, 2014 TWiPO #23 ~ Neuroblastoma Jeopardy 2011
January
26, 2012
In 2011 there were over 1300 new articles
published on neuroblastoma in the medical literature.
Join Dr. Tim Cripe and his co-host Dr. Lars
Wagner in a fast-paced, in-depth, and comprehensive survey of 18 of the most
important papers on neuroblastoma published in 2011. Dr. Cripe and Dr Wagner
explore and discuss the compelling evidence reported on a variety of topics,
including epidemiology, risk stratification, clinical trials, ALK mutation and
expression, new targets, and genetics.
All of the papers discussed are listed HERE with links to PubMed.
Please send all comments and questions to [email protected]
...more
41min
February 10, 2014 TWiPO #22 ~ Brain Tumor Year-End Round Robin
December
05, 2011
Join Dr. Tim Cripe and his co-host Dr. Lionel
Chow for a fast-paced, in-depth, and comprehensive survey of 15 important
recent papers on pediatric brain tumor research, addressing medulloblastoma,
ependymomas, and gliomas. Dr. Cripe and Dr. Chow explore and discuss the
compelling evidence reported on a variety of topics, including viral causes and
therapeutic implications, biomarkers, genomics, proteomics, targets, classification,
risk stratification, treatment side-effects, proton-beam radiation therapy, and
results of recent clinical trials.
This robust review of current research includes
all of the following papers [click link], listed by timed location in the podcast.
Please send all comments and questions to
[email protected]
...more
49min
February 10, 2014 TWiPO #21 ~ Interview with Dr. Beatrice Lampkin
November
29, 2011
Dr. Tim Cripe and co-hosts Dr. Maureen O'Brien
and Dr. Raj Nagarajan interview a pediatric hematology/oncology legend, Dr.
Beatrice Lampkin, who served as Director of Cincinnati Children's Division of
Hematology/Oncology in the 1970’s. This enlightening and inspiring discussion
explores her career and her contributions to leukemia therapy and the
challenges she faced as an early leader in the field as a female. She describes
her experience with polio, paralysis from the neck down, crutches for mobility,
and later, her confinement to a wheelchair. Revealing another era in
communications with parents and patients in the 1960s and 1970s, she explains
how parents were advised to use the term "anemia" to describe their
child's condition rather than "leukemia" to to explain why the child
would require periodic blood transfusions, in order to prevent shunning by
friends and family. Dr. Lampkin also shares her satisfaction in following the
earliest survivors of pediatric cancer she treated who are now in their 40s and
50s.
As if all that isn't inspiring enough, she
describes her busy retirement in which she continues to teach the Cincinnati
Children's Hospital fellows how to examine blood and bone marrow smears under
the microscope and her work in the founding of the GLAD House (http://www.gladhouse.org/),
a sanctuary to help drug-addicted youth get off the streets.
Please send all comments and questions to
[email protected].
...more
38min
February 10, 2014 TWiPO #20 ~ The F-word in Pediatric Cancer Research
November
15, 2011
Today’s episode features an impressive lineup
for a hot topic. Host Dr. Tim Cripe warns: “If your blood isn’t boiling by the
end, you weren't listening.” Hear Tim and co-host Dr. Lionel Chow discuss
pediatric cancer research funding with guests Dr. C. Patrick (Pat) Reynolds, Dr.
E. Anders (Andy) Kolb, and parent Joe McDonough.
Dr. Pat Reynolds puts government spending on
the number one disease killer of children in the US in perspective, comparing
the tiny $200M spent on pediatric cancer research to the foreign aid budget of
$22B (less than 1%). For example, $1.6B goes to Egypt alone. The COG budget is
a mere $46M. The DOD budget is $700B. See his slides here. Dr. Lionel Chow mentions an enlightening fact
– private donations to St Jude exceed $600M per year, on top of the givers’
paying taxes. This is 3 times the entire NCI budget for pediatric cancer
research for all institutions in the US.
Spending per Person Years Life Lost is compared
for childhood cancers and adult cancers, see graph here.
Dr. C Patrick Reynolds is Director, Cancer
Center and Professor of Cell Biology & Biochemistry, Internal Medicine, and
Pediatrics, School of Medicine, Texas Tech University Health Sciences Center,
Lubbock TX. Dr. E Anders Kolb is the Director of Blood and Bone Marrow
Transplantation at Alfred I. duPont Hospital for Children, and Head of the
Cancer Therapeutics Laboratory at Nemours Biomedical Research, Wilmington, DE.
Joe McDonough is father to Andrew, and founder of The Andrew McDonough B+ (Be Positive)
Foundation, raising money for families and research.
Please send comments to
[email protected]
...more
40min
February 10, 2014 TWiPO #19 ~ More on Hedgehog signaling, brain tumor risk from cell phone use, and FDA approval of cancer drugs
October
30, 2011
Several just-published papers in the literature
relate to recent podcast episodes, and host Dr. Tim Cripe and co-host Dr. Lionel Chow review these interesting
developments.
0:55 Hedgehog Signaling: Recent papers
discussing this pathway in neuroblastoma and rhabdomyosarcoma are discussed,
with implications for treatment in these tumor types with itraconozole.
6:40 Cell phone and brain tumor risk: The
controversy concerning criticism by the Environmental Health Trust of a study
showing that cell phone use does not increase risk of brain tumors in children
is explored.
Accelerated approval of cancer drugs by the FDA
and implications for pediatric cancers.
15:30 Brentuximab for two types of lymphoma
21:20 Vemurafenib for melanoma
28:30 Crizotinib for non-small cell lung cancer
(and potential use in neuroblastoma)
42:30 Response to email regarding personalized
medicine TWiPO episode #17 and lab blog for Dr Charles Keller at OHSU
References:
Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8.
doi: 10.1002/pbc.23174. Hedgehog pathway activity in
pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report
from the Children's Oncology Group.
Int J Oncol. 2011 Oct;39(4):899-906. doi:
10.3892/ijo.2011.1076. Pharmacological inhibition of
the Hedgehog pathway preventshuman rhabdomyosarcoma cell growth.
Cancer Lett. 2011 Nov 28;310(2):222-31. Inhibition of the sonic hedgehog
pathway by cyplopaminereduces the CD133+/CD15+ cell compartment and the in
vitrotumorigenic capability of neuroblastoma cells.
Cell Phone Study Was Flawed, Say Some Experts by
Roxanne Nelson Medscape Oncology News.
The JNCI Study by Aydin et al on Risk of Childhood Brain Cancer from
Cellphone Use Reveals Serious Health Problems, Environmental Health Trust.
N Engl J Med. 2010 Nov 4;363(19):1812-21. Brentuximab
vedotin (SGN-35) for relapsed CD30-positive lymphomas.
FDA Approves Brentuximab for Two Lymphomas By:
ELIZABETH MECHCATIE, Oncology Report Digital Network.
Clin Cancer Res. 2011 Oct
15;17(20):6428-36. Brentuximab Vedotin (SGN-35).
FDA Approves Vemurafenib for Advanced Melanoma.
By: JANE SALODOF MACNEIL, Oncology Report Digital Network.
N Engl J Med. 2011 Jun
30;364(26):2507-16. Improved survival with
vemurafenib in melanoma with BRAFV600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2547-8. Been
there, not done that--melanoma in the age of molecular therapy. http://www.ncbi.nlm.nih.gov/pubmed/21639809
Biochem J. 2011 Aug 15. Activating ALK mutations found in neuroblastoma are inhibited by
Crizotinib and NVP-TAE684.
N Engl J Med. 2010 Oct
28;363(18):1693-703. Anaplastic lymphoma kinase inhibition in non-small-cell
lung cancer.
Nature. 2007 Aug 2;448(7153):561-6. Epub 2007
Jul 11. Identification of the transforming EML4-ALK fusion gene in non-small-cell
lung cancer.
Science. 1994 Mar 4;263(5151):1281-4. Fusion of a kinase gene, ALK, to
a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
...more
46min
February 10, 2014 TWiPO #18 ~ Targeting EWS-FLI1 in Ewing's Sarcoma: Interview with Dr Jeff Toretsky
October
18, 2011
Host Dr. Tim Cripe and co-host Dr. Lionel Chow
welcome special guest Dr. Jeff Toretsky on TWiPO to discuss his clinical and
research interest in Ewing's sarcoma. Dr. Toretsky explains the challenges of
developing a clinical grade drug from a small molecule for a specific target
such as EWS-FLI1. The small market for a disease like Ewing's creates
formidable hurdles for researchers, yet Dr. Toretsky is driven on by the
question "If I don't do this, who will?" (17:54 mins)
Dr. Jeff Toretsky is Professor of Oncology and
Pediatrics at Georgetown University. He graduated with BS in Biochemistry from
University of Wisconsin, Madison, WI, and recieved his MD from University of
Minnesota, Minneapolis, MN. He completed fellowship training at the NCI
Pediatric Branch.
Please send any questions or comments to
[email protected]
...more
23min
February 10, 2014 TWiPO #17 ~ Personalized medicine: Interview with Dr Giselle Sholler
October
13, 2011
Host Dr. Tim Cripe and co-hosts Dr. Lars Wagner
and Dr. Lionel Chow welcome guest Dr. Giselle Sholler on this episode of TWiPO.
Dr. Sholler gives the background to her current research interest in
neuroblastoma, and describes her nifurtimox trials and how she formed the
Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC).
The physicians also discuss the specifics of the personalized medicine
feasibility trial now open for neuroblastoma.
Dr. Sholler is a Pediatric Oncologist with
Spectrum Health Medical Group, Helen DeVos Childrens Hospital, and directs the
Pediatric Oncology Therapeutic Discovery Clinic. She is also Co-Director of the
VARI/TGen Pediatric Oncology Research Program, and Associate Professor of the
Neuroblastoma Translational Research Laboratory at Van Andel Research
Institute. She has a faculty appointment within Michigan State University's
College of Human Medicine, and continues as adjunct faculty at University of
Vermont. Dr. Sholler is also a Guest Researcher in the Pediatric Oncology Branch
at the NCI.
References:
J Clin Oncol. 2010 Nov 20;28(33):4877-83. Epub
2010 Oct 4. Pilot study using molecular profiling of patients' tumors to find
potential targets and select treatments for their refractory cancers.
Science 16 Sept 2011: Vol. 333 no. 6049 pp.
1569-1571. Pushing the Envelope in Neuroblastoma Therapy
Mol Cancer Ther August 2011 10; 1311. A Pilot
Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with
Advanced Cancer
...more
39min
February 10, 2014 TWiPO #16 ~ Genetic Underpinnings of Ewing Sarcoma: Interview with Dr Stephen L. Lessnick
October
07, 2011
Dr. Tim Cripe and co-hosts Dr. Lionel Chow and
Dr. Lars Wagner welcome special guest Dr. Stephen Lessnick for an in-depth
discussion on the progress to date in understanding the genetics of Ewing's
sarcoma. The challenges of interpreting the gene expression data as well as the
ethics of collecting tumor specimens for research purposes are also explored.
Dr.Stephen Lessnick is a Professor of Pediatrics and Oncological Sciences at
the University of Utah, where he also serves as an Attending Physician in
Pediatric Hematology/Oncology at Primary Children's Medical Center in Salt Lake
City, UT. He received his PhD in Molecular Biology from UCLA in 1994, and his
MD from UCLA in 1996, followed by a residency at Children's Hospital in Boston,
and a fellowship at the Dana-Farber Cancer Institute and Children's Hospital.
Currently, Dr. Lessnick is the Director of the Center for Children's Cancer
Research at Huntsman Cancer Institute, a Jon and Karen Huntsman Presidential
Professor in Cancer Research at the University of Utah, and is the Vice Chair
for Biology of the Bone Tumor Committee in the Children's Oncology Group.
Please send questions or comments to [email protected]
...more
39min
February 10, 2014 TWiPO #15 ~ MicroRNAs and hereditary cancer
September
28, 2011
Join host Dr. Tim Cripe with his co-hosts Drs.
Jim Geller, Lionel Chow, and Lars Wagner in a robust discussion with special
guest Dr. Kathryn Wikenheiser-Brokamp on the implications of DICER1, rare tumor
registries, and difficult issues surrounding genetic counseling.
Kathryn A. Wikenheiser-Brokamp, MD, PhD, is an
Associate Professor in Pathology and Pulmonary Biology at Cincinnati Children's
Hospital Medical Center. Her research is focused on pediatric and adult lung diseases,
including cancer. She seeks to determine the molecular mechanisms underlying
Rb/p16, p53, and Dicer1 pathway function in lung development and the
pathogenesis of lung disease. Dr. Wikenheiser-Brokamp holds a PhD in
Developmental Biology, Developmental Biology and an MD from University of
Cincinnati.
Papers discussed:
DICER1 syndrome: clarifying the diagnosis, clinical features and
management implications of a pleiotropic tumour predisposition syndrome.
J Med Genet. 2011 Apr;48(4):273-8.
Extending the Phenotypes Associated with DICER1 Mutations.
Hum Mutat. 2011 Aug 31. doi: 10.1002/humu.21600.
Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1
mutations: a report from the International Pleuropulmonary Blastoma Registry.
Gynecol Oncol. 2011 Aug;122(2):246-50.
Please send questions or comments to
[email protected]
...more
47min

FAQs about This Week in Pediatric Oncology:

How many episodes does This Week in Pediatric Oncology have?

The podcast currently has 115 episodes available.